In July 2023, Alberta Health Services renegotiated a contract with MHCare for children’s pain medication, raising its value from about $49 million to $56 million. Forensic accountants who later reviewed the documentation said they could not find support for the $56 million figure.
That is the claim set beside the record. What follows rests on reporting of the addendum report to retired Manitoba justice Raymond Wyant, who engaged the forensic accounting firm RSM. The Tribune has not seen the full report.
The forensic review could not support the price
RSM examined the contract documentation. Its addendum report concluded that it could not find support for the $56 million contract value based on the documentation reviewed. The $7 million increase is the gap in the paper.
Alberta received about $20 million of usable medication
The medication was sourced from Atabay Pharmaceuticals, a Turkish supplier. Alberta bought roughly $20 million worth of usable product. The bottles carried expiration dates between January and April 2026, so even that supply has now run out of shelf life. AHS said it would take legal steps to recover between $42 million and $50 million for medication it never received.
By simple subtraction, which is Tribune arithmetic and not a published figure, $56 million committed less $20 million received leaves $36 million of value that was undelivered, unusable or undocumented. The recovery range is larger than that gap, and the reporting does not explain the difference.
A fair account would carry AHS’s answer on the July 2023 renegotiation. It is not in the material behind this column.
The procurement record leaves three questions open
First, who authorized the move from $49 million to $56 million, and what internal review applied. Increases of that size in public procurement normally come with a written rationale, and if one exists, the forensic accountants did not find it.
Second, what due diligence tested MHCare’s capacity to deliver. Failing to supply the contracted volume points either to thin vetting of the supplier or to a supply chain problem nobody tracked after signing.
Third, what oversight sat between signature and the point where non-delivery became clear. Contracts of this size usually carry milestone payments, delivery checks and triggers for remedies. AHS is now pursuing legal recovery, which suggests those protections were absent or did not work.
A lawsuit recovers money but does not explain a decision
Pursuing $42 million to $50 million from an international vendor is expensive and slow, and full recovery is not guaranteed. Legal costs reduce the net return to taxpayers, and resolution may be years away. The judge’s investigation was a necessary step, but a review that cannot explain the pricing leaves the question open.
These were public dollars spent inside a public health system on medication for children. Alberta Health Services holds the internal records of the July 2023 renegotiation that would settle why the price rose by $7 million, and the Government of Alberta could release the addendum report in full.




